Last reviewed · How we verify
NCT04440410
Evaluation of Cutaneous and Circulating Inflammatory Biomarkers in Hidradenitis Suppurativa and Atopic Dermatitis
trial in Hidradenitis Suppurativa in 40 participants. Completed in 24 March 2021.
24 March 2021
Quick facts
| Lead sponsor | Kymera Therapeutics, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 28 May 2020 |
| Primary completion | 24 March 2021 |
| Estimated completion | 24 March 2021 |
| Sites | 1 location across Canada |
Conditions studied
- Hidradenitis Suppurativa — all drugs for Hidradenitis Suppurativa →
- Dermatitis, Atopic — all drugs for Dermatitis, Atopic →
Sponsor
Kymera Therapeutics, Inc. — full company profile →
Who can join
18 and older, any sex, with Hidradenitis Suppurativa or Dermatitis, Atopic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This non-intervention study will identify the biomarker profiles in hidradenitis suppurativa (HS) and atopic dermatitis (AD) (as a comparator) that would have the most utility in interventional studies evaluating efficacy during therapeutic intervention. Study data will also be used to correlate cellular/molecular changes in blood (cells and serum), and tissue, with clinical/histopathological phenotypes.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS.
Trowbridge JJ, Starczynowski DT. · · 2021 · cited 153× · PMID 34129017 · DOI 10.1084/jem.20201544 -
Thiazole: A Versatile Standalone Moiety Contributing to the Development of Various Drugs and Biologically Active Agents.
Arshad MF, Alam A, Alshammari AA, Alhazza MB, et al · · 2022 · cited 70× · PMID 35807236 · DOI 10.3390/molecules27133994 -
IRAK4 Is Overexpressed in Hidradenitis Suppurativa Skin and Correlates with Inflammatory Biomarkers.
McDonald A, Karnik R, Campbell V, Davis J, et al · · 2025 · cited 5× · PMID 39084489 · DOI 10.1016/j.jid.2024.04.035
Verify or expand the search:
- PubMed search for NCT04440410
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hidradenitis Suppurativa
Currently open trials in the same condition.
- NCT07244263 — A Study of Zasocitinib in Adults With Hidradenitis Suppurativa · Phase 2 · recruiting
- NCT07225569 — A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Sup · Phase 2 · recruiting
- NCT07243782 — Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cose · recruiting
- NCT07282015 — Real-world Secukinumab Outcomes in Canadian HS Patients · recruiting
- NCT07228390 — A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps · Phase 2 · recruiting
Other Kymera Therapeutics, Inc. trials
Trials by the same sponsor.
- NCT06945458 — Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD) · Phase 1 · completed
- NCT06673667 — First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants · Phase 1 · completed
- NCT05775406 — Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemi · Phase 1 · completed
- NCT05233033 — Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL · Phase 1 · completed
- NCT05225584 — Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leuke · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04440410 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kymera Therapeutics, Inc.
- Last refreshed: 13 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04440410.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing